ImmuneWalk Therapeutics
Modulating Immune and Inflammatory Disease by Preventing Myeloid Cells from Entering Inflamed Tissue
Company Overview
Snapshot
Founded in October 2023 by Prof Dror Harats, Sam Backenorth, and Erez Feige, ImmuneWalk Therapeutics operates with 1–10 employees. The company has raised $7 million across one funding round and recently announced positive topline Phase 1 SAD data for its immunology and inflammation drug candidate, IW-601, in June 2025.
Business overview
ImmuneWalk Therapeutics is a clinical-stage company developing novel therapies for chronic inflammatory diseases. Its core technology, Monocyte Targeting Technology (MTT), is designed to selectively block the migration of monocytes from the bloodstream into inflamed tissues. The company is advancing its solution, IW-601, to a Phase 1 clinical trial, targeting conditions such as Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Non-Alcoholic Steatohepatitis within the Health Tech & Life Sciences sector.
Strategic signal
ImmuneWalk Therapeutics announced positive topline Phase 1 SAD data for its immunology and inflammation drug candidate, IW-601, in June 2025. This clinical milestone is a significant validation of the company's Monocyte Targeting Technology, indicating potential efficacy and safety for a novel therapeutic approach to chronic inflammatory diseases. For investors, this signals strong progress in its clinical development pipeline and de-risks future investment in the company's innovative drug candidates.
Log in to access full profile ›Company Intelligence Q&A
- What is ImmuneWalk Therapeutics' primary focus?
- ImmuneWalk Therapeutics focuses on developing novel therapies for chronic inflammatory diseases by preventing myeloid cells from entering inflamed tissue.
- When was ImmuneWalk Therapeutics founded and by whom?
- ImmuneWalk Therapeutics was founded in October 2023 by Prof Dror Harats, Sam Backenorth, and Erez Feige.
- What is the company's core technology?
- The company's core technology is Monocyte Targeting Technology (MTT), which is designed to selectively block the migration of monocytes from the bloodstream into inflamed tissues.
- What was a recent significant clinical development for ImmuneWalk Therapeutics?
- In June 2025, ImmuneWalk Therapeutics announced positive topline Phase 1 SAD data for its immunology and inflammation drug candidate, IW-601.
- What was ImmuneWalk Therapeutics' most recent funding activity?
- In May 2025, ImmuneWalk Therapeutics announced a $7 million Seed financing round.